treat obesity

  • Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity. (
  • At present, many oriental medicinal herbs are reported to effectively treat obesity without significant side effects and might be an excellent alternative strategy to develop safe and effective antiobesity drugs [ 8 , 9 ]. (
  • Orlistat is a drug designed to treat obesity. (
  • Used on a short-term basis clinically to treat obesity, some appetite suppressants are also available over-the-counter. (


  • Clinically available antiobesity agents include orlistat, a pancreatic lipase inhibitor, and sibutramine, a centrally acting inhibitor of serotonin and norepinephrine uptake [ 3 , 4 ]. (
  • For that reason orlistat was chosen over lipstatin for development as an anti-obesity drug. (
  • Initially orlistat was developed as a treatment for dyslipidemia, not as an anti-obesity agent. (
  • However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug. (
  • Orlistat is used for the treatment of obesity. (


  • Most primary care settings do not provide much obesity treatment, though, as primary care providers (PCPs) are not well trained and because reimbursement for treatments is not consistent. (
  • The remainder of the registry's patients can still receive obesity treatment but will not be reimbursed. (
  • Impact: If the study is successful, we plan to take the results to the leaders at Denver Health to see if they will make obesity treatment more broadly available for all patients there. (
  • Paitents will be randomized to receive either placebo or topiramate, an anti-seizure medication not approved for the treatment of bipolar disorder, in addition to their lithium or valporate. (
  • 5-HT2C receptor agonists are attractive drug targets that have potential use in the treatment of a number of conditions including obesity, psychiatric disorders, sexual dysfunction and urinary incontinence. (
  • Subsequently, these receptors became a promising pharmacotherapeutic target for further investigation for the treatment of obesity. (
  • Later, 5-HT2C receptors were proposed as a therapeutic target for the treatment of multiple central nervous system (CNS) disorders including: psychiatric disorders, obesity, sexual dysfunction and urinary incontinence. (
  • It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity. (
  • AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. (
  • Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis. (
  • E-6776) is a drug acting as a CB1 receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity. (
  • It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. (
  • It had been approved in Europe for the treatment of obesity but has not received approval in the United States or Canada due to safety concerns. (
  • Because of potential side effects, and limited evidence of small benefits in weight reduction especially in obese children and adolescents, it is recommended that anti-obesity drugs only be prescribed for obesity where it is hoped that the benefits of the treatment outweigh its risks. (
  • Current and potential anti-obesity drugs may operate through one or more of the following mechanisms: Catecholamine releasing agents such as amphetamine, phentermine, and related substituted amphetamines (e.g., bupropion) which act as appetite suppressants are the main tools used for the treatment of obesity. (
  • Based on its effectiveness for hypothyroidism, thyroid hormone became a popular treatment for obesity in euthyroid people. (
  • Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but the limitations of anti-angiogenic therapy have been shown in practice. (
  • Inhibiting angiogenesis requires treatment with anti-angiogenic factors, or drugs which reduce the production of pro-angiogenic factors, prevent them binding to their receptors or block their actions. (
  • Weight loss maintenance is one of the most difficult aspects of obesity treatment and so this effect is promising. (


  • To treat and control obesity, pharmacological approaches such as drugs to induce loss of appetite, inhibit nutrient absorption, and promote weight loss have been used [ 2 ]. (
  • Bangpoongtongsungsan (BPT), a traditional herbal medicine composed of 18 crude drugs, has been used as an antiobesity drug in overweight patients [ 6 ]. (
  • The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard anti-epileptic drugs. (
  • Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. (
  • Anti-obesity medication or weight loss drugs are pharmacological agents that reduce or control weight. (


  • Another notable agent is rimonabant, a cannabinoid receptor antagonist marketed as an anti-obesity agent which was withdrawn shortly after its introduction due to the incidence of severe psychiatric side effects associated with its use including depression, anxiety, and suicidal ideation. (


  • The dysfunctions in question may contribute to many of the adverse metabolic conditions associated with obesity and the associated metabolic syndrome. (
  • It was first reported in 1996 to cause a body fat loss effect in rats in the International Journal of Obesity and Related Metabolic Disorders. (


  • The antiobesity effects of a P. aviculare ethanol extract (PAE) in high-fat diet- (HFD-) induced obese mice were investigated. (
  • These results suggest that PAE exerts antiobesity effects in HFD-induced obese mice through the suppression of lipogenesis in adipose tissue and increased antioxidant activity. (


  • Development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued, likely due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly-acting agents. (
  • Yukioka H. A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent. (


  • The 5-HT2c receptor agonist Fenfluramine (market names Pondimin, Ponderax and Adifax) was discovered in 1972 as a result of research performed to identify anorectic compounds lacking the effects of psycho-stimulants and sympathomimetic agents (such as amphetamines). (
  • However it was still considered a successful proof of concept of the potential of Y5 receptor antagonists as possible anti-obesity agents in future. (


  • The present invention comprises a transdermal drug delivery device comprising a reservoir comprising a releasably stored dosage of a pharmaceutically active agent and a translucent film adjacent to at least a portion of the reservoir, wherein the translucent film comprises at least one inorganic ultraviolet-absorbing. (
  • 15 . A transdermal drug delivery device according to claim 1 , wherein the pharmaceutically active agent may undergo ultraviolet light induced degradation. (
  • A closely related type of drug is a serotonin-dopamine releasing agent (SDRA). (
  • Lipase inhibitors belong to a drug class that is used as an antiobesity agent. (
  • Cetilistat, a new lipase inhibitor, is an experimental drug for obesity. (
  • doi: 10.1021/acs.oprd.5b00023 George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. (

weight loss

  • Agents that increase energy expenditure and weight loss by neural and chemical regulation. (


  • Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to the withdrawal of products from the market. (


  • Lipase inhibitors are classified in the ATC-classification system as A08AB (peripherally acting antiobesity products). (


  • Obesity is associated with numerous chronic diseases and increased cardiovascular mortality. (


  • In a study in Zucker rats, which are genetically predisposed to obesity, Garcinia cambogia extract containing HCA showed that high doses led to significant suppression of epididymal fat accumulation, but also had high testicular toxicity. (


  • When researchers found out that it promotes less energy uptake, the focus was switched to obesity. (


  • The compound was found to potently induce body-fat loss while preserving protein stores in animals which is the ultimate goal of an anti-obesity agent as body protein loss is an undesired but inevitable (to some degree) side effect of fat loss via calorie restriction. (


  • A range of treatments have shown to be effective for treating obesity. (


  • The problem of obesity is becoming a worldwide problem. (